Cargando…
BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies
Synergistic molecular vulnerabilities enhancing hypomethylating agents in myeloid malignancies have remained elusive. RNA-interference drug modifier screens identified antiapoptotic BCL-2 family members as potent 5-Azacytidine-sensitizing targets. In further dissecting BCL-X(L), BCL-2 and MCL-1 cont...
Autores principales: | Bogenberger, J M, Kornblau, S M, Pierceall, W E, Lena, R, Chow, D, Shi, C-X, Mantei, J, Ahmann, G, Gonzales, I M, Choudhary, A, Valdez, R, Camoriano, J, Fauble, V, Tiedemann, R E, Qiu, Y H, Coombes, K R, Cardone, M, Braggio, E, Yin, H, Azorsa, D O, Mesa, R A, Stewart, A K, Tibes, R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131248/ https://www.ncbi.nlm.nih.gov/pubmed/24451410 http://dx.doi.org/10.1038/leu.2014.44 |
Ejemplares similares
-
The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia
por: Tibes, Raoul, et al.
Publicado: (2015) -
Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia
por: Tibes, Raoul, et al.
Publicado: (2019) -
RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma
por: Arora, Shilpi, et al.
Publicado: (2010) -
Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients
por: Kortuem, K M, et al.
Publicado: (2016) -
Azacytidine Treatment for VEXAS Syndrome
por: Raaijmakers, Marc H. G. P., et al.
Publicado: (2021)